Table 4.

Associations Among Patient Characteristics and MoCA Scores Based on Tumor Location Groups, N = 71

		Brain, Brain + Spine				Spine
		n	%	Median MoCA Score	% With Abnormal MoCAa	n	%	Median MoCA Score	% With Abnormal MoCAa
Total		58	100	26	36	13	100	28	15
Sex	Female	26	45	26	35	7	54	29	14
	Male	32	55	27	38	6	46	28	17
Ethnoracial group	White/Hispanicb	10	17	27	40	2	15	29	0
	White/non-Hispanic	44	76	26	34	11	85	28	18
	Missing	4	7	24	50	0	0		0
Education	High school	7	12	23	71	1	8	29	0
	College	49	88	27	33	11	92	28	18
KPS group	Poor (<=80)	24	41	26	46	3	23	28	33
	Good (>=90)	31	53	27	29	10	77	29	10
Recurrence	No	31	53	27	26	10	77	28	20
	Yes	27	47	26	48	3	23	29	0
Tumor grade	Low grade (I/II)	11	19	27	27	11	85	27	18
	High grade (III/IV)	45	78	26	40	2	15	30	0
Radiation	No	11	19	26	18	6	46	28	20
	Yes	47	81	26	40	7	54	29	13
Levetiracetam use	No	31	53	26	36	13	100	27	15
	Yes	27	47	26	37	0	0		0
Dexamethasone use	No	53	91	26	36	12	92	28	8
	Yes	5	9	26	40	1	8	16	100
Sites	Single	41	71	27	32
	Multiple	16	28	26	44
	Missing	1	2	24	100
Tumor side	Right	35	60	26	40
	Left	13	22	27	31
	Left + right	3	5	25	67
	Posterior fossa	3	5	28	0
	Brainstem/midline	3	5	27	0
	Missing	1	2	24	100
Frontal lobe involvement	Frontal	25	43	26	40
	Elsewhere	32	55	27	31
	Missing	1	2	24	100

Abbreviations: KPS, Karnofsky performance status; MoCA, Montreal Cognitive Assessment.

^aAbnormal = MoCA score ≤25.

^bIncludes Asian, Black/African American, Native Hawaiian/Pacific Islander, and Hispanic/Latino.